Circ_LDLR promotes the progression of papillary thyroid carcinoma by regulating miR-1294/HMGB3 axis.
HMGB3
ceRNA
circ_LDLR
miR-1294
papillary thyroid carcinoma
Journal
Journal of biochemical and molecular toxicology
ISSN: 1099-0461
Titre abrégé: J Biochem Mol Toxicol
Pays: United States
ID NLM: 9717231
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
19
06
2023
received:
09
03
2023
accepted:
31
07
2023
pubmed:
11
8
2023
medline:
11
8
2023
entrez:
11
8
2023
Statut:
ppublish
Résumé
Circular RNAs (circRNAs) have been found to be associated with the development and progression of cancers including papillary thyroid carcinoma (PTC). Circ_LDLR has been reported to be highly expressed in PTC, but its underlying mechanism of action has not been fully elucidated. This study aimed to investigate the role of circ_LDLR in PTC. The expression of circ_LDLR, miR-1294 and high mobility group box (HMGB) 3 was detected by quantitative real-time polymerase chain reaction (qRT-PCR). CCK-8 assay and transwell assays were employed to value cell viability, invasion and migration abilities. Western blot assay was to detect HMGB3 protein expression. Luciferase reporter gene and pull down assay were used to validate the interaction between miR-1294 and HMGB3 or circ_LDLR. Circ_LDLR showed high expression levels in PTC tissues and cells and knockdown of it inhibited the growth, invasion, and migration of PTC cells. In addition, miR-1294 was considered as a downstream target of circ_LDLR, and inhibition of miR-1294 partially reversed the inhibitory effects of circ_LDLR knockdown on PTC cells growth, invasion, and migration. More importantly, HMGB3 was identified as a downstream target of miR-1294. Our findings suggest circ_LDLR may plays a promoting role in PTC by downregulating miR-1294 and upregulating HMGB3 expression. Therefore, circ_LDLR may serve as a valuable prognostic biomarker and therapeutic target for PTC.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e23498Subventions
Organisme : Medical Science Research Project of Henan Province
ID : 182102310233
Organisme : Medical Science Research Project of Henan Province
ID : 2018020764
Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
F. Nabhan, P. H. Dedhia, M. D. Ringel, Int. J. Cancer 2021, 149(5), 984.
Y. Yin, S. Hong, S. Yu, Y. Huang, S. Chen, Y. Liu, Q. Zhang, Y. Li, H. Xiao, Int. J. Endocrinol. 2017, 2017, 1.
M. E. Cabanillas, D. G. McFadden, C. Durante, Lancet 2016, 388(10061), 2783.
H. Teng, F. Mao, J. Liang, M. Xue, W. Wei, X. Li, K. Zhang, D. Feng, B. Liu, Z. Sun, Theranostics 2018, 8(16), 4345.
Q. Lin, Q. Qi, S. Hou, Z. Chen, N. Jiang, L. Zhang, C. Lin, Bioengineered 2021, 12(2), 10136.
Y. Wang, H. Zong, H. Zhou, Bioengineered 2021, 12(1), 1484.
L. Zeng, S. Yuan, P. Zhou, J. Gong, X. Kong, M. Wu, Bioengineered 2021, 12(2), 11795.
P. Li, J. Chen, J. Zou, W. Zhu, Y. Zang, H. Li, Bioengineered 2022, 13(3), 7181.
W. Bi, J. Huang, C. Nie, B. Liu, G. He, J. Han, R. Pang, Z. Ding, J. Xu, J. Zhang, J. Exp. Clin. Cancer Res. 2018, 37(1), 275.
W. Zhang, T. Liu, T. Li, X. Zhao, Cancer Gene Ther. 2021, 28(3-4), 279.
Z. Li, X. Huang, A. Liu, J. Xu, J. Lai, H. Guan, J. Ma, Life Sci. 2021, 264, 118622.
X. Gui, Y. Li, X. Zhang, K. Su, W. Cao, Cancer Cell. Int. 2020, 20, 241.
O. Balacescu, D. Sur, C. Cainap, S. Visan, D. Cruceriu, R. Manzat-Saplacan, M. S. Muresan, L. Balacescu, C. Lisencu, A. Irimie, Int. J. Mol. Sci. 2018, 19(12), 3711.
D. Zhou, X. Lin, P. Wang, Y. Yang, J. Zheng, D. Zhou, Bioengineered 2021, 12(1), 2106.
J. Liu, S. Yan, J. Hu, D. Ding, Y. Liu, X. Li, H. S. Pan, G. Liu, B. Wu, Y. Liu, Bioengineered 2021, 12(1), 8457.
W. Ma, X. Zhao, Y. Gao, X. Yao, J. Zhang, Q. Xu, Bioengineered 2022, 13(2), 4411.
Z. Wang, J. Yan, T. Zou, H. Gao, Oncol. Lett. 2018, 16(2), 2243.
W. Pan, L. J. Pang, H. L. Cai, Y. Wu, W. Zhang, J. C. Fang, Eur. Rev. Med. Pharmacol. Sci. 2019, 23(9), 3719.
Z. F. Zhang, G. R. Li, C. N. Cao, Q. Xu, G. D. Wang, X. F. Jiang, Eur. Rev. Med. Pharmacol. Sci. 2018, 22(24), 8582.
B. Wen, Y. Wei, K. Zhao, Mol. Cell. Biochem. 2021, 476(4), 1729.
Z. Zhang, Y. Chang, J. Zhang, Y. Lu, L. Zheng, Y. Hu, F. Zhang, X. Li, W. Zhang, X. Li, PLoS One 2017, 12(7), e0179741.
S. Guo, Y. Wang, Y. Gao, Y. Zhang, M. Chen, M. Xu, L. Hu, Y. Jing, F. Jing, C. Li, Q. Wang, Z. Zhu, Med. Sci. Monit. 2016, 22, 3951.
M. Li, Y. Cai, H. Zhao, Z. Xu, Q. Sun, M. Luo, L. Gu, M. Meng, X. Han, H. Sun, Tumor Biol. 2015, 36(6), 4785.
B. Han, J. Chao, H. Yao, Pharmacol. Ther. 2018, 187, 31.
B. Lei, Z. Tian, W. Fan, B. Ni, Int. J. Med. Sci. 2019, 16(2), 292.
Y. Zhang, D. D. Jia, Y. F. Zhang, M. D. Cheng, W. X. Zhu, P. F. Li, Y. F. Zhang, Int. J. Biol. Sci. 2021, 17(7), 1731.
X. Wen, J. Du, X. Wang, Int. J. Biol. Markers. 2021, 36(4), 10.
H. Zheng, Q. Fu, K. Ma, S. Shi, Y. Fu, Endocr. J. 2021, 68(11), 1247.
K. Liu, L. Li, A. Rusidanmu, Y. Wang, X. Lv, Cell. Physiol. Biochem. 2015, 36(1), 100.
H. Guan, J. Liu, P. Lv, L. Zhou, J. Zhang, W. Cao, Oncol. Rep. 2020, 44(4), 1385.
H. Guan, G. Shang, Y. Cui, J. Liu, X. Sun, W. Cao, Y. Wang, Y. Li, J. Cell. Physiol. 2019, 234(6), 8998.
Y. Yu, G. Dong, Z. Li, Y. Zheng, Z. Shi, G. Wang, Int. J. Oncol. 2022, 60(4), 38.
J. Ge, M. Liu, Y. Zhang, L. Xie, Z. Shi, G. Wang, J. Biochem. Mol. Toxicol. 2022, 36(6), e23031.
J. Xi, Y. Xi, Z. Zhang, Y. Hao, F. Wu, B. Bian, G. Hao, W. Li, S. Zhang, Cell Cycle 2021, 20(19), 2040.
Y. Li, Y. Ma, T. Zhang, C. Feng, Y. Liu, Biol. Chem. 2020, 401(10), 1191.